In the search for a tumour suppressor gene in the 3p21.3 region we isolated two genes, RBM5 and RBM6. Gene RBM5 maps to the region which is homozygously deleted in the small cell lung cancer cell line GLC20; RBM6 crosses the telomeric breakpoint of this deletion. Sequence comparison revealed that at the amino acid level both genes show 30% identity. They contain two zinc finger motifs, a bipartite nuclear signal and two RNA binding motifs, suggesting that the proteins for which RBM5 and RBM6 are coding have a DNA/RNA binding function and are located in the nucleus. Northern and Southern analysis did not reveal any abnormalities. By SSCP analysis of 16 lung cancer cell lines we found only in RBM5 a single presumably neutral mutation. By RT-PCR we demonstrated the existence of two alternative splice variants of RBM6, one including and one excluding exon 5, in both normal lung tissue and lung cancer cell lines. Exclusion of exon 5 results in a frameshift which would cause a truncated protein of 520 amino acids instead of 1123 amino acids. In normal lung tissue, the relative amount of the shorter transcript was much greater than that in the lung tumour cell lines, which raises the question whether some tumour suppressor function may be attributed to the derived shorter protein.
Introduction
According to results of cytogenetic deletion analysis, loss of heterozygosity studies and chromosome transfer experiments, the distal region of 3p21 might be the location of a kind of broad spectrum tumour suppressor gene involved in the development of a variety of cancers. 1 We described earlier a homozygous deletion of 440 kb in the 3p21.3 region of a small cell lung cancer (SCLC) cell line, GLC20. 2 Because this deletion has a 370 kb overlap with the 3p homozygous deletions of two other SCLC cell lines 3, 4 and affects a region within a 2 Mb fragment showing tumour suppressor activity, we used the region corresponding to the deletion as a starting point for gene isolation. Here we describe the genomic structures and expression patterns of two genes with RNA/DNA binding features which we found in this region and which show an overall similarity of 30% at the derived amino acid level.
Materials and Methods

Cell Lines
The lung cancer cell lines analysed in this study have been described previously. 6 
Isolation of YAC DNA
Culturing of yeast cells, generation of agarose plugs and isolation and digestion of YAC DNA were performed as previously described. [7] [8] [9] 
Direct Screening of cDNA Libraries
The oligo-dT primed NALM-6 pre-B-cell library in lambda ZAP was kindly provided by Dr André Bernards (Charlestown, Mass., USA). An oligo-dT primed human lung library in lambda DR2 was purchased from Clontech (Palo Alto, USA). Screening of the cDNA libraries was performed by direct hybridisation with YAC DNA as we have described earlier. 9 
Screening of PAC Libraries
A PAC was obtained by screening the RPCI-1 and RPCI-6 libraries (Genome Technology Centre, Leiden, The Netherlands) cloned in the vectors pCYPAC2 and pPAC4 respectively with the RBM6 cDNA as probe.
Southern and Northern Analyses
DNA analysis was performed using standard protocols. Total RNA was isolated using RNAzol (Campro Scientific, Veenendaal, NL) and analysed according to standard protocols. Multi-tissue polyA + -filters were purchased from Clonetech (Palo Alto, USA).
Sequence Analysis
cDNA clones were sequenced using an automatic fluorescent sequencer (ALF; Pharmacia, Uppsala, Sweden) with the Thermosequenase 10 cycle sequencing kit 11 from Amersham (Buckinghamshire, UK) or using T7 polymerase with fluorescent dATP. 12 Small fragments were sequenced manually using T7-polymerase sequencing kit (Sequenase, Pharmacia, Uppsala, Sweden).
Rapid Amplification of cDNA Ends (RACE)
RACE-PCR was performed using human lung 5'RACEready total cDNA and human lung Marathon-Ready total cDNA (Clontech, Palo Alto, USA) according to the protocols provided by the manufacturer.
Determination of the Intron-Exon Structure
Intron/exon structures were determined by Vectorette-PCR 13 and by comparing the cDNA sequences to publicly available sequences of the 3p21 sequencing project from the Washington University Genome Sequencing Center.
SSCP Analysis
Exons or exon fragments were amplified using standard protocols. Electrophoresis was performed under two different conditions; a 6% PAA gel with 10% glycerol and a PAA MDE gel (AT Biochem, Malvern, USA).
RT-PCR
RNA was isolated from lung cancer cell lines with the use of the RNAeasy Mini Kit (Qiagen Inc, Santa Clarita, USA); cDNA was synthesised with the use of the Ready To Go YouPrimed First Strand kit (Pharmacia, Uppsala, Sweden) and random primers. cDNA fragments were amplified using standard protocols and primers Gfra1F in exon 4 (5' tct taa tgc ttt gac tcc) and Gfra1R2 in exon 7 (5' ggc ttg ata cat act cca gg).
Results
Isolation of RBM5 and RBM6
The overlapping YACs 181H1 and 181B3 originate from the chromosomal segment corresponding to the GLC20 deletion and its vicinity. 2 Using YAC 181H1 DNA as probe in a direct hybridisation to the pre-B-cell cDNA library, followed by further screening of this library, we isolated several clones together resulting in a cDNA with a total length of 3.1 kb. In a northern blot analysis of RNA from heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas two bands were detected: one band of 7.4 kb and one of 3.5 kb. Expression was seen in all tissues investigated. We named the gene concerned RBM5 (standing for RNA Binding Motifs) for reasons described below.
Direct hybridisation of the lung cDNA library with YAC 181B3 DNA, followed by 5'-RACE PCR and 5'Marathon-RACE PCR, resulted in the isolation of several clones representing together a cDNA with a total length of 3.7 kb. In a northern blot analysis of the same tissues that expressed RBM5, three different bands were observed of 4.7 kb, 3.9 kb and 2.1 kb, respectively. We named the gene concerned RBM6, again for reasons given below.
In Southern blot analysis, RBM5 did not hybridise to DNA from GLC20, confirming that the gene maps to the region homozygously deleted in this SCLC cell line. Although also a cDNA clone representing the 3' end of RBM6 did not hybridise to DNA from GLC20, implying that this part of the gene is in the deletion, a cDNA clone representing the 5' end of RBM6 did hybridise to GLC20, indicating that the RBM6 gene overlaps one of the deletion breakpoints of GLC20. Pulsed field gel analysis was used to map the genes in the known restriction map. 2, 14 Both RBM5 and RBM6 hybridised to a 650 kb NotI fragment, a 380 kb NruI Related genes in 3p21 critical lung cancer region T Timmer et al t fragment and a 350 kb NruIxNotI fragment, confirming that they map between the NotI-containing clone DD1 and UBE1L, and that RBM6 overlaps the telomeric breakpoint of GLC20 (Figure 1 ).
Sequence Analysis of RBM5 and RBM6
The RBM5 cDNA clones defined an open reading frame of 2460 nucleotides. In this frame, a stop codon is present at bp positions 2594-2596 and is followed by an untranslated region of 504 nucleotides. A likely ribosome-binding site 15 precedes a first methionine codon at bp positions 149-151. Taking this as the transcription initiation site, a protein product of 815 amino acids can be inferred. From the lengths of the cDNA (3.1 kb) and the transcript on the northern blot (3.5 kb), some 400 bp appear to be missing at the 5' end, presumably either due to alternative processing or untranslated regions.
The sequence of RBM6 contains an open reading frame of 3375 nucleotides. A likely ribosome-binding site precedes an initiating methionine codon at bp positions 134-136. A stop codon is present at bp positions 3503-3505 and is followed by an untranslated region of 120 nucleotides. Taking the methionine at position 134 as the start of transcription, a protein product of 1123 amino acids can be inferred. From the lengths of the cDNA (3.7) and the transcript on the northern blot (3.9 kb), some 200 bp appear to be missing at the 5' end, again presumably either due to alternative processing or untranslated sequences.
Sequence analysis of RBM5 and RBM6 revealed that the two genes show a 30% similarity at the derived amino acid level. A homology search of DNA sequences in the GenBank databases with the BlastN program revealed that RBM5 is identical (differing by only 4 bp) to Luca-15, a gene recently isolated from the 3p21.3 region.
16 RBM5 also shows a similarity to DXS8237E 17 
/KIAA0122
18 on Xp11.23 of 51% at the amino acid level and a comparable similarity to the rat equivalent S1-1. 19 A homology search for RBM6 revealed that this gene is identical (differing by only 3 bp) to the cDNA sequence NY-LU-12, 20 (differing by only 4 bp) to the cDNA sequence DEF-3 (accession no. AF069517) and to the cDNA sequence g16 (accession no. U50839). The mouse homolog Def-3 has a similarity to RBM6 of 82% at the amino acid level.
The derived amino acid sequences of RBM5 and RBM6 share functional motifs, as also reported by Güre et al. 20 These include two RNA binding motifs, 21 two zinc finger motigs (one of the C 2 C 2 type and one of the C 2 H 2 type) and a bipartite nuclear signal. 22 The RNA binding motifs in RBM6 are, however, much less conserved than in RBM5 (Figure 2) . Moreover, the derived RBM6 protein contains in its first 290 amino acids 20 repeats of 6 amino acids separated by intervals of 4 to 6 amino acids. The consensus sequence of the
Intron/Exon Structure Comparison
The intron/exon boundaries of RBM5 were obtained by comparing the cDNA sequence of RBM5 with the genomic sequences from the Washington University Genome Sequencing Center. The RBM5 gene has 25 exons ranging in size from 61 bp (exon 8) to 627 bp (exon 25) ( Table 1 ). The intron/exon boundaries of RBM6 were obtained by vectorette PCR with the use of the PAC isolated by hybridisation to the RBM6 cDNA clone (exons 1-5, 8, 9, 12-20) and by comparing the cDNA sequence of RBM6 with the genomic sequence from the Washington University Genome Sequencing Center (exons 6, 7, 10, 11). The RBM6 gene has 20 exons ranging in size from 43 bp (exon 11) to 1279 bp (exon 2) ( Table 2) . From the H3938P1.contig 13 sequence from the Washington University Genome Sequencing Center it can be concluded that there is a large intron ( > 34 kb) between exon 5 and exon 6 of RBM6. By comparing the amino acid translations of the different exons, the RBM5 exons 4, 6, 7, 8, 10, 11, 22, 23, and 24, respectively, appeared to have a high similarity (more than 25%) to the RBM6 exons 3, 5, 6, 7, 9, 10, 17, 18, and 19, respectively ( Figure 3 ).
By PCR with primer sets specific for the different exons of RBM6, we could determine that the homozygous deletions of the SCLC cell lines GLC20 and NCI-H740 include the larger part of RBM6. GLC20 contains exons 1-5 and NCI-H740 contains exons 1-6.
Mutation Analysis of RBM5 and RBM6
Fourteen SCLC lung cancer cell lines and one non-SCLC cell line have been subjected to northern and Southern analysis using the RBM5 and RBM6 clones as probes. No variations in expression, nor deletions or other rearrangements were found. In a search for possible small mutations, SSCP analysis of RBM5 and RBM6 was performed on 14 SCLC cell lines and two non-SCLC cell lines. For RBM5, band shifts were observed for exons 3, 4, 12 and 22 in several SCLC cell lines as well as in unrelated normal control samples. In GLCA2, an adenocarcinoma cell line, a band shift, not seen in DNA from blood lymphocytes from 70 controls, was observed for exon 15. Sequence analysis of the aberrant band revealed a change at position 1341 (codon 398) of GGC to GTC, resulting in an amino acid change of glycine to valine.
Because the intron-exon boundaries of exons 1 to 5 of RBM6 had not yet been determined when the SSCP analysis was performed, these exons were amplified with overlapping exon-specific primer sets using cDNA derived from total RNA as a template. Band shifts for exons 2, 15 and 16 were seen in some of the cell lines. Band shifts for exons 15 and 16 were, however, also observed in unrelated normal controls. The band shift for exon 2 was only seen in one of the non-SCLC cell lines and not in 70 controls. Sequence analysis of the aberrant band revealed a codon change of GAG to GAA at position 340 (codon 69) resulting in a silent glutamic acid mutation.
Alternative Splicing in RBM6
An earlier version of g16 in GenBank missed 74 bp with respect to our RBM6 sequence. When we had determined the intron-exon boundaries of RBM6, it appeared that these 74 bp coincide with exon 5. Using primers on each side of this exon, in exons 4 and 7, RT-PCR on cDNA from normal lung tissue specimens, SCLC cell lines and one non-SCLC cell line, gave in all cases a 260 bp product including exon 5 and a 186 bp product excluding this exon, as verified by sequence analysis. It also appeared, however, that there was a difference in the intensity ratio of the two PCR products between normal lung cDNA and SCLC cDNA. Whereas in normal lung tissue, the shorter product had half the amount of the longer one, 10 of the 12 SCLC cell lines and the sole non-SCLC cell line analysed expressed substantially less of the shorter product than of the longer product (Table 3, Figure 4 ).
Discussion
We isolated two genes, RBM5 and RBM6, which both map to the 3p21.3 region. RBM5 has a homolog on the X chromosome, DXS8237E at Xp11.23. For this gene a rat homolog, S1-1, is known. Functionality tests of S1-1 revealed that its protein product, synthesised by in vitro translation, binds to RNA homopolymers, with a preference for G and U polyribonucleotides and little affinity to poly(A). 19 The amino acid sequences derived from the genes belonging to the RBM5 family (RBM5, DXS8237E and S1-1) show two RNA-binding motifs, two potential zinc finger domains and a bipartite nuclear signal (Figure 2) , suggesting that the protein products are located in the nucleus and have a RNA/ DNA binding function.
Sequence comparison also led to the conclusion that RBM6 is another member of the RBM5 family. At the amino acid level both genes show 30% identity. They share some clusters of exons that have a high sequence similarity (Figure 3) . Whereas the RBM6 protein also contains the two zinc finger domains and the nuclear signal present in the RBM5 protein, its RNA-binding motifs are much less conserved. The octamers at the corresponding positions in RBM6 have only five amino acids that fit the RNP-1 pattern (Figure 2) . The N-terminal part of RBM6 (aa1-300), contains 20 repeats of six amino acids. The consensus sequence D-F/Y-R-G/D-R/G-D/E of the repeats, separated by four to six amino acid intervals, is not found in other known genes. A repeat sequence with some similarity to the consensus repeat sequence of the RBM6 repeat is, however, found six times in the C-terminal amino acid sequence of Nopp44/46, a tyrosine-phosphorylated protein of Trypanosoma brucei ( Figure 5 ). Nopp44/46 localises to the nucleolus and in vitro binding experiments have demonstrated that this protein is capable of binding nucleic acids with a preference for poly (U). 23 Therefore, the function of RBM6 might still be comparable with the function of RBM5.
The sequence of RBM6 is identical to the sequence of the NY-LU-12 gene, cloned by screening a recombinant lung cancer cDNA expression library with autologous patient serum. 20 Patient sera showed anti-NY-LU-12 seroreactivity in two of 21 allogenic lung cancer patients. A mutation search was performed on DNA from a sole anti-NY-LU-12 seroreactive patient, but no NY-LU-12 mutations could be detected.
Although RBM5 is located in the region which we consider critical for the development of lung cancer, northern and Southern analysis of RBM5 in a number of lung cancer cell lines did not reveal any aberrant Related genes in 3p21 critical lung cancer region T Timmer et al t patterns. The 7.4 kb band detected on northern blots in addition to the 3.5 kb band most likely represents a premessenger RNA. SSCP analysis of RBM5 revealed a single mutation in an adenocarcinoma cell line substituting valine for glycine at amino acid position 398. Because both amino acids belong to the same nonpolar group, this change will most likely not affect the function of the protein. In blood lymphocytes from 70 control individuals no such mutation was found.
The 3' end of RBM6 (exons 6-20) also maps to this critical region homozygously deleted in GLC20, but the 5' end of this gene (exons 1-5) crosses the telomeric breakpoint of the deletion. Exons 6-20 are present on H3938P1.contig13 (Washington University Genome Sequencing Center). Although this contig contains 34 kb upstream to exon 6, it does not contain exons 1-5. This means that an intron of at least 34 kb is located between exons 5 and 6. We were able to determine, in agreement with results published by Wei et al, 16 that RBM6 also crosses the telomeric breakpoint of the homozygous 3p deletion of the NCI-H740 SCLC cell line. That breakpoint appeared to be located between exons 6 and 7. Thus, in two different SCLC cell lines, RBM6 is interrupted by homozygous deletions. Still, as in the case of RBM5, neither northern, nor Southern, nor SSCP analysis revealed any aberrant pattern or mutation in 15 other lung cancer cell lines. The 4.7 kb band detected on northern blots in addition to the 3.9 kb band may well represent a premessenger RNA. Since also a 2.1 kb is detected on northern blots, RBM6 may also show splice variants. By RT-PCR, we could demonstrate another alternative splicing, namely of exon 5. One variant includes exon 5, the other variant misses the 74 bp that represent exon 5. This deletion of 74 bp will result in a truncated protein of 520 amino acids instead of 1123 amino acids. Because of the frameshift caused by the 74 bp deletion, the last 26 amino acids at the C-terminus differ from those at the same position in the non-deleted form ( Figure 6 ). Both variants occur in normal lung tissue as well as in SCLC Gels were scanned and peak areas were measured and normalised for bp length. The ratios are the average of three independent experiments (except in the normal lung 5 specimen where the average of two experiments is given). cell lines. In normal lung tissue, the amount of the shorter product is in general about half the amount of the longer product (Figure 4 ). In the lung cancer cell lines, however, the amount of the shorter product is in many cases lower than 5% of the amount of the longer product. On average, the relative amount of the shorter product in normal lung tissue was 4.5 times that in the lung cancer cell lines. Thus, in a relative sense, normal lung tissue contains much more truncated protein than lung tumour cell lines. If RBM6 were to represent a tumour suppressor gene, one would expect the opposite result, unless some tumour suppressor function may be attributed to the shorter protein. The question remains as to which regulatory mechanism is involved in reversing the proportions of the shorter and longer variants when cells become malignant. Alternative splicing is often regulated in a tissue, sex, and/or developmental stage-specific fashion 24, 25 and regulated by factors that are expressed in a tissue-specific manner and are necessary for the splicing events to occur. 26 It may thus well be possible that proliferating cells have different regulation of splicing. This might explain why cultured fibroblasts show a transcript pattern similar to that shown by the lung cancer cell lines. 
